Winston Hide, Ph.D., is the co-director of the NonCoding RNA Precision Diagnostics and Therapeutics Core Facility at Beth Israel Deaconess Medical Center and an Associate Professor at Beth Israel Department of Pathology. He moved to Boston in 2019 from the UK, where he has been the professor and chair of computational biology at the Sheffield Institute of Translational Neuroscience in the Department of Neuroscience and Department of Computer Science at the University of Sheffield. Prior to going to UK Hide was an associate professor of bioinformatics and computational biology at the Harvard T.H. Chan School of Public Health. A visiting faculty member at the Massachusetts Institute of Technology' s Computer Science and Artificial Intelligence Laboratory, Hide is the founding director of the Harvard Stem Cell Institute Center for Stem Cell Bioinformatics.
Dr. Hide received his bachelor's degree in zoology from the University of Wales, Cardiff, and his doctorate degree in molecular genetics from Temple University, Philadelphia. He performed his postdoctoral training at the University of Texas, Houston, at the Baylor College of Medicine and at the Smithsonian Institution Museum of Natural History. He gained industry experience in Silicon Valley at the MasPar Computer Corporation while serving as director of genomics. Dr. Hide founded the South African National Bioinformatics Institute, where he coauthored the South African Government Biotechnology Strategy. He won the Oppenheimer Foundation Distinguished Sabbatical Research Fellowship in 2007 and received the Oppenheimer medal.
Dr. Hide was elected into the Academy of Science of South Africa in 2007. He was the first recipient of the "International Society for Computational Biology Award for Outstanding Achievement," given in recognition of his work for the development of computational biology and bioinformatics in Africa.
Dr. Hide applies systems biology approaches to genomic data to reveal and drug critical disease processes occurring in cancer and neurodegeneration. This strategy can be used to build and implement systems that allow discovery and prioritization of key target genes and processes in involved in cancer and drug resistance. Dr. Hide has been funded by key industry partners, including Biogen Inc., to develop translational pipelines for target prioritization.